{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T07:10:24Z","timestamp":1732950624957,"version":"3.30.0"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.pcad.2024.10.014","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:55:27Z","timestamp":1730422527000},"page":"97-99","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Safety outcomes of oral anticoagulants in patients with an indication of anti-coagulants after TAVR: A meta-analysis"],"prefix":"10.1016","volume":"87","author":[{"given":"Ahmed","family":"Abdelaziz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karim","family":"Atta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed Farid","family":"Gadelmawla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Abdelaziz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Desouky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasmin","family":"Negida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed A.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dua Abdelraouf","family":"Eldosoky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Helmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shrouk","family":"Ramadan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emad","family":"Singer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Tafur-Soto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.pcad.2024.10.014_bb0005","first-page":"e35","article-title":"2020 ACC\/AHA guideline for the Management of Patients with Valvular Heart Disease: Executive summary: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"143","author":"Otto","year":"2021","journal-title":"Circulation"},{"issue":"29","key":"10.1016\/j.pcad.2024.10.014_bb0010","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1093\/eurheartj\/ehac242","article-title":"Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial","volume":"43","author":"Collet","year":"2022","journal-title":"Eur Heart J"},{"issue":"23","key":"10.1016\/j.pcad.2024.10.014_bb0015","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1056\/NEJMoa2111016","article-title":"Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR","volume":"385","author":"Van Mieghem","year":"2021","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.pcad.2024.10.014_bb0020","doi-asserted-by":"crossref","first-page":"e1066","DOI":"10.4244\/EIJ-D-22-00521","article-title":"Continued non-vitamin K antagonist oral anticoagulants versus vitamin K antagonists during transcatheter aortic valve implantation","volume":"18","author":"Mangner","year":"2023","journal-title":"EuroInterven\u202f: J EuroPCR in Collaborat Work Group Intervent Cardiolof the European Society of Cardiology"},{"issue":"1","key":"10.1016\/j.pcad.2024.10.014_bb0025","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11239-019-01968-w","article-title":"Comparison of warfarin versus DOACs in patients with concomitant indication for oral anticoagulation undergoing TAVI; results from the ATLAS registry","volume":"50","author":"Kalogeras","year":"2020","journal-title":"J Thromb Thrombolysis"},{"issue":"16","key":"10.1016\/j.pcad.2024.10.014_bb0030","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.jcin.2019.03.003","article-title":"Oral anticoagulant type and outcomes after Transcatheter aortic valve replacement","volume":"12","author":"Jochheim","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"issue":"22","key":"10.1016\/j.pcad.2024.10.014_bb0035","first-page":"1706","article-title":"Direct oral anticoagulants versus vitamin K antagonist after transcatheter aortic valve implantation","volume":"109","author":"Hohmann","year":"2023","journal-title":"Heart (British Cardiac Society)"},{"issue":"9","key":"10.1016\/j.pcad.2024.10.014_bb0040","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00392-018-1247-x","article-title":"NOAC monotherapy in patients with concomitant indications for oral anticoagulation undergoing transcatheter aortic valve implantation","volume":"107","author":"Geis","year":"2018","journal-title":"Clini Res Cardiol\u202f: OffJ German Cardiac Soci"},{"issue":"15","key":"10.1016\/j.pcad.2024.10.014_bb0045","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.jcin.2021.05.025","article-title":"TAVR patients requiring anticoagulation: direct Oral anticoagulant or vitamin K antagonist?","volume":"14","author":"Didier","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"issue":"3","key":"10.1016\/j.pcad.2024.10.014_bb0050","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jcin.2023.11.038","article-title":"Non-vitamin K antagonist versus vitamin K antagonist Oral anticoagulant agents after Transcatheter aortic valve replacement","volume":"17","author":"Alaour","year":"2024","journal-title":"JACC Cardiovasc Interv"},{"issue":"15","key":"10.1016\/j.pcad.2024.10.014_bb0055","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.jcin.2021.06.020","article-title":"Antithrombotic therapy after Transcatheter aortic valve replacement","volume":"14","author":"Capodanno","year":"2021","journal-title":"JACC Cardiovasc Interv"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062024001506?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062024001506?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T06:54:22Z","timestamp":1732949662000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062024001506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":11,"alternative-id":["S0033062024001506"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2024.10.014","relation":{},"ISSN":["0033-0620"],"issn-type":[{"type":"print","value":"0033-0620"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety outcomes of oral anticoagulants in patients with an indication of anti-coagulants after TAVR: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2024.10.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}